Tommaso Grassi

Gyn. Special interest in GynOnc. No COI. Tweets are my own. Happily married

[IJGC @IJGConline]

#LeadArticle 🚨 #Prognostic value of #ITC in #SLN in low risk #endometrial cancer by @Cucinella_G
Link 🖇️ https://t.co/lRMdFrRCWi
@MayoClinic @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4

[FIGO HQ @FIGOHQ]

Join a panel of experts for a #FIGOWebinar on the updated 2023 FIGO endometrial cancer staging system.

📅 Thursday 24 August, 16:00 UTC+1
💬English with live interpretation in French and Spanish

➡️ https://t.co/xP6LE4BKDv

[IJGC @IJGConline]

🌟 NEW RELEASE 🌟
🎬 Educational #Video Lecture series 🎬
📄 🏥 "ESGO Peri-operative #OvarianCancer Guidelines" w Prof. C Fotopoulou
🔗https://t.co/JcReRw6ZQM
@CF_PC_OvCaGroup @ESGO_society @GynMe4 @me4_so @pedroramirezMD @SPeritoneum @IGCSociety @lchiv4 #GynCancer #Surgery

[Ross Harrison, MD MPH @RossFH]

Great #gynonc surgery videos with excellent narration describing the procedure & anatomy -- wish I had found these at the start of fellowship: https://t.co/7FfPifLhSS @DavidCibula @IJGCfellows @SGO_org @IGCSociety #gyncsm #FOAMed #oncsurgery

[ENGAGe.ESGO @EngageEsgo]

It’s #CervicalScreeningAwarenessWeek June 20-26. The @ESGO_society Prevention Committee & ENGAGe want you to help spread the word!
💜For laypeople:
Brochure on screening 👉https://t.co/zQzDXdvgZa
Cervical cancer factsheet 👉 https://t.co/vJrDzhtuac

@JoTrust @ENYGO_official

[Mario M. Leitao, Jr @leitaomd]

Amazing group meeting discussing current topics in endometrial cancer care and future directions! We were at Mayo but also with MD Anderson colleagues. ⁦@TeamEndo_MSK⁩ ⁦@TeamOvary_MSK⁩ ⁦@MayoClinic⁩ ⁦@MDAndersonNews⁩

[ENGAGe.ESGO @EngageEsgo]

Today is World Ovarian Cancer Day! #WOCD2022 Let’s spread awareness about the disease and support for patients living with it! 💜💙💜

#nowomanleftbehind #nopersonleftbehind @ENYGO_official @ESGO_society @IJGConline

[Pedro T Ramirez @pedroramirezMD]

#OvarScore is here!! Download it today https://t.co/Jyy9XOY4ou #DESKTOPIII #SOC1 #secondarycytoreduction #ovariancancer @IJGCfellows @IGCSociety @ESGO_society @IJGConline

[Gian Micalessin @gianmicalessin]

Così seguendo le tracce del suo viaggio in Iraq ho scoperto la grandezza e il coraggio di questo Papa

[IJGC @IJGConline]

The @ESGO_society @ESTRO_RT &ESP #guidelines for #EndometrialCancer are hot off the press. Click link for free access👇📄👇
Great collaboration, congratulations!
https://t.co/83rNj3xRM2
#GYNonc @GynMe4 @me4_so @pedroramirezMD @OncoAlert @IGCSociety #Cancer #MedTwitter #GYN

[MSKCC Team Uterus @TeamEndo_MSK]

SEntinel Lymph node Endometrial Cancer Trial (SELECT) is currently underway! With results expected in 2026, this study will assess the safety of the SLN algorithm in patients with Stage I, intermediate-risk #endometrioid #EndometrialCancer. Led by @sloan_kettering’s @aburustummd

[IJGC @IJGConline]

#ClinicalTrial
"Prospective multicenter single-arm observational study on the oncological safety of the SLN algorithm in st I intermediate-risk #EndometrialCancer (SELECT Trial)"
https://t.co/fLYxEiH7gJ
@PamSolimanMD @aburustummd @TommasoGrassi85 @sgpedranobre @GynMe4

[lorenzo ceppi @ceppi_lorenzo]

Out now in gyneocology oncology- Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers ⁦@GynMe4⁩ ⁦⁦@ESGO_society⁩

[IJGC @IJGConline]

"Two ultrastaging protocols for the detection of lymph node metastases in early-stage cervical and endometrial cancers"
https://t.co/ftR7BZglKX
#GYNoncology #Surgery #Cancer #CervicalCancer #EndometrialCancer @GynMe4 @IJGCfellows @ENYGO_official

[European Network of Young Gynae Oncologists @ENYGO_official]

#ENYGO & @ESGO_society Tumor Board🔔

🇮🇹Dr. Alessandro Buda

💥Management of #EndometrialCancer patients

💥Debate on the management of #EndometrialCancer after surgery in the sentinel node era

🗓7 October 2020
⏰18:00 CEST

Register Now👇🏽
https://t.co/fr1ShGfLHd

#ESGOevents

[JAMA Network Open @JAMANetworkOpen]

Cohort study finds 11 of 17 women later diagnosed with high-grade serous epithelial ovarian cancer (HGS-EOC) had TP53 clonal variants detected in Papanicolaou test samples up to 6 years prior. https://t.co/RAdFZGsVxN